Boston Scientific Corporation (BSX) has entered into a definitive agreement to acquire Intera Oncology Inc., a Boston-based life science company. The acquisition expands the company’s interventional oncology offerings with the Intera 3000 Hepatic Artery Infusion Pump and floxuridine — a chemotherapy drug — both of which are approved by the FDA.The transaction is expected to close in the first half of 2025, subject to closing conditions. Boston Scientific expects the deal to have an immaterial impact on adju ...